Holen Sie sich die Stockscreener-App
14.14
2.82%
-0.41
Handel nachbörslich:
14.14
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
DBV Technologies (NASDAQ:DBVT) Shares Up 6.2%Here's Why - MarketBeat
European ADRs Started The Week Slightly Higher In US Trading - Finimize
MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT) - Stock Titan
DBV technologies S.A. (ADR) (DBV1.SG) balance sheet - Yahoo Finance UK
DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4%Time to Buy? - MarketBeat
RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding - Stock Titan
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - The Manila Times
DBV Technologies Announces Sale of Approximately $50 - GlobeNewswire
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Canada
Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim - The Globe and Mail
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT) - Seeking Alpha
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk - Moomoo
DBV Technologies stock falls on $150M share offering plan - Investing.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
DBV Technologies Plans Viaskin Peanut Launch Prep, If Approved - Stock Titan
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027 - scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report - markets.businessinsider.com
DBV Technologies (NASDAQ: DBVT) sees $174.9M cash and Q3 2027 runway - Stock Titan
DBV Technologies Announces the Filing of its 2026 Half-Year - GlobeNewswire
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 - markets.businessinsider.com
DBV Technologies' July 16 webcast will cover Q2 results - Stock Titan
ETFs Investing in DBV Technologies SA Sponsored ADR Stocks - TradingView
Europe’s US-Listed ADRs Slipped Late Tuesday Morning - Finimize
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - markets.businessinsider.com
DBV Technologies S.A. - Via Ritzau
DBV Technologies posts half-year liquidity contract figures - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing - The Manila Times
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A40WEX Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
European ADRs Rose In US Trading Late Thursday Morning - Finimize
DBV1 Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index - markets.businessinsider.com
DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial - Yahoo Finance
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
DBV Technologies Screens First Infant in THRIVE Peanut Patch Trial - HCPLive
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 - The Manila Times
Peanut patch helps allergic kids with asthma and eczema in trial - Stock Titan
DBV Technologies to Present New Positive Data from VITESSE - GlobeNewswire
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
European ADRs Slip As Nokia And Sequans Lead Declines - Finimize
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):